International Journal of Prevention and Treatment

International Journal of Prevention and Treatment publishes the essential forum for new developments in the theory, research and practice of prevention. Prevention Science serves as a forum designed to disseminate new developments in the theory, research and practice of prevention.

Bert Johansson

Editorial Board Member of International Journal of Prevention and Treatment

Associate Professor, Texas Tech Health Sciences Center El Paso, Dept Pediatrics, USA

Research Areas

Influenza, Dengue, Vaccines, Outcomes

Education

1993M.D.Tulane University of Louisiana, School of Medicine, New Orleans, LA
1988Ph.DMicrobiology, Department of Microbiology, Mt Sinai School of Medicine, City University of New York, New York, NY
1981B.S.Biochemistry and Psychology, Tulane University, College of Arts and Sciences, New Orleans, LA

Experience

2009-presentAssociate Professor, Department of Biomedical Sciences, Center for Infectious Diseases and Clinical Associate Professor, Department of Pediatrics, Division of Critical Care Medicine, Texas Tech University Health Sciences Center-El Paso, Paul L. Foster Sch
2008-2010Pediatric Hospitalist/Intensivist, Northern Westchester Hospital, 400 East Main Street Mt Kisco, NY 10549
1999-2009Chief Scientific Officer, (2002-2009) Senior Scientist/Project Director (1999-2002); Influenza Vaccine Development; Innovation Biosciences, Armonk, New York
2000-2009General Pediatrician/Pediatric Critical Care (locums tenems), Weatherby Locums 6451 N. Federal Highway, Suite 800, Ft. Lauderdale, FL 33308
2001-2010General Pediatrician, Carmel Pediatrics, 11 Fair St, Carmel NY 10512
2005-2006Temporary Federal Employee, Department of Health and Human Services; Physician. Hurricanes Katrina and Rita Disaster Relief, Baton Rouge, LA
2002-2004Fellow, Division of Pediatric Critical Care, Cornell-Weill Medical Center New York, New York
1998-2000Assistant Professor/Attending Pediatric Emergency Room, Department of Pediatrics, Babies and Children's Hospital, Columbia-Presbyterian Medical Center, New York
1993-1998Assistant Professor, Department of Microbiology & Immunology, New York Medical College, Valhalla, NY
1996-1998Resident (PGY 2-3), Department of Pediatrics, Babies and Children's Hospital, Columbia-Presbyterian Medical Center, New York, NY
1993-1994Resident (PGY1), Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA
1988-1992Fellow, Department of Microbiology, Mt Sinai School of Medicine, City University of New York, New York, NY
1983-1988Graduate Assistant/NIH Trainee: Department of Microbiology, Mt Sinai School of Medicine, City University of New York, New York, NY

Academic Achievement

Physician Recognition Award with Commendation, American Medical Association, 2007
American Academy of Pediatrics, Continuing Medical Education/Continuing Professional Development Award, 2003-10
Student Senate Excellence in Teaching Award New York Medical College, Valhalla, NY, 1997
Owl Club, Tulane University School of Medicine Outstanding Teaching Award, 1994
Greater New Orleans Pediatric Society Award for Outstanding Medical Student, 1993
American College of Physicians Award for Excellence In Medicine, Alpha Omega Alpha, 1993
Young Investigator Award, Interscience Conference on Antimicrobial Agents & Chemotherapy-American Society of Microbiology, (Support from Mercke-Sharpe & Dohme), 1988

Membership

Member, Infections Control World Organization , 2006
Member, Society for Critical Care Medicine, Subsection on Pediatric Medicine, 2004
Das Kinderberg International Pediatric Relief-United Nations Mission in Kosova , 2002
Fellow, American Academy of Pediatrics, Subsection for Critical Care Medicine and Subsection on Hospice and Palliative Care, 1993
Doctors Without Borders/Medicines Sans Frontiers: Honduras, Dominican Republic
Member, Harvey Society of the Rockefeller University, New York, NY, 1988
Member, American Society of Virology; American Society of Microbiology1987

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Bottone, E.J., Toma, M., Johansson, B.E., and Wormser, G.P. 1985.Capsule Deficient Cryptococcus neoformans in AIDS patients. The Lancet I, 400-401.
[2]  Bottone, E.J., Toma, M., Johansson, B.E., Wormser, G.P. 1986.Poorly encapsulated Cryptococcus neoformans from patients with AIDS I:Preliminary observations. AIDS Research. 2:211-218.
[3]  Johansson, B.E., Moran, T.M., Bona, C.A., Popple, S. W., and Kilbourne, E.D. 1987. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin II:Sequential infection of mice simulates human experience. J. Immuno. 139: 2010-2014.
[4]  Johansson, B.E., Moran, T.M., Bona, C.A., and Kilbourne, E.D. 1987. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin III: Reduced generation of neuraminidase specific Helper T cells in hemagglutinin primed mice. J. Immuno. 139: 2015-2019.
[5]  Johansson, B.E., Moran, T.M., and Kilbourne, E.D. 1987 Antigen-presenting B cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci, USA. 84: 6869-6873.
[6]  Mayer, R., Ioannides, C., Johansson, B.E., and Bona, C.A. 1987. Effect of syngenic anti-idiotype antibody on influenza virus neuraminidase antibody response. Viral Immuno I:121-139.
[7]  Johansson, B.E., Bucher, D.J., and Kilbourne, E.D. 1989.Purified influenza virus hemagglutinin and neuraminidase are equivalent immunogens J. Virology. 63, 3:1239-1246.
[8]  Price, P.M., Reichelder, C.F., Johansson, B.E., Kilbourne, E.D., and Acs, G. 1989. Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B and influenza A virus. Proc Natl Acad Sci., USA 86: 1453-1456.
[9]  Meeks, K.A., Johansson, B.E., Bona, C.A., Shulman, J., and Capra, D. 1989.Nucleotide changes in sequential variants of influenza virus hemagglutinin genes and molecular structure of corresponding monoclonal antibodies specific for each variant. Proc Natl Acad Sci, USA. 86:4664-4668.
[10]  Johansson, B.E., Bucher, D. J., Pokorny, B.A. and Kilbourne, E.D. 1989. Identification of PR-8 M1 protein influenza high-yield reassortants by M1-specific monoclonal antibodies. Virology 171;634-636.
[11]  Kilbourne, E.D., Johansson, B.E., and Grajower, B. 1990. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci, USA. 87:786-756.
[12]  Johansson, B.E., and Kilbourne, E.D. 1990. Comparative long term effects in a mouse model system of influenza whole virus vaccine and purified neuraminidase vaccine followed by sequential infections. J. Inf.Dis.162: 800-809.
[13]  Johansson, B.E., and Kilbourne, E.D. 1991. Programmed antigenic stimulation: Kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus vaccine or neuraminidase vaccine. Vaccine 9, 5:330-333.
[14]  Johansson, B.E., and Kilbourne, E.D. 1991 Comparison of intranasal and aerosol infection of mice in assessment of immunity to influenza virus infection. J. Virol Meth. 35:109-114.
[15]  Johansson, B.E., and Kilbourne, E.D. 1992. Influenza vaccine strain selection: Equivalence of two antigenically distinct hemagglutinin variants of 1989 H3N2 influenza virus in protection of mice. Vaccine 10, 9:603-606.
[16]  Kilbourne, E.D., Johansson, B.E., Moran, T.M., Wu, S., Pokorny, B.A., Xu, X., and Cox, N. 1993. Implications for vaccine production of influenza A virus hemagglutinin polymorphism. Pleotropic antigenic variant of A/Shangai/11/87 (H3N2) virus selected as high-yield reassortant J Gen Virol. 74:1311-1316.
[17]  Johansson, B.E., Gradjower, B., and Kilbourne, E.D. 1993 Infection permissive immunization with influenza virus neuraminidase prevents weight loss of infected mice. Vaccine 10:1037-1039.
[18]  Johansson, B.E., and Kilbourne, E.D. 1993. Disassociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virology. 67, 10:5721-5723.
[19]  Johansson, B.E., and Kilbourne, E.D. 1994. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition Proc Natl Acad Sci, USA. 91: 2358-2361.
[20]  Johansson, B.E., and Beckerman, R.C. 1994. "Respiratory Syncytial Virus and Bronchiolitis: Current Perspectives." Pulmonary Inf Dis 1, 6: 1-8.
[21]  Johansson, B.E., Price, P.M., and Kilbourne, E.D.1995. Immunogenicity of influenza A virus N2 neuraminidase produced in insects larvae by baculovirus recombinants. Vaccine 13: 841-845.
[22]  Kilbourne, E. D., Couch, R.B., Kasel, J.A., Keitel, W.A., Cate, T.R., Quarles, J.H., Grajower, B., Pokorny, B.A., and Johansson, B.E. (1995). Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine. 13: 18, 1799-1804.
[23]  Powers, D.C., Johansson, B.E., and Kilbourne, E.D. 1996. Neuraminidase-specific antibody responses to inactivated influenza virus vaccines in young and elderly adults. Clin Diag Lab Immuno. 3:5. 511-516.
[24]  Johansson, B.E., and Kilbourne, E.D. 1996. Dissociation of influenza virus neuraminidase from matrix and nulceoprotein eliminates cognate help and antigenic competition. Virology. 225:136-144.
[25]  Johansson, B.E.., Matthews , J.T., and Kilbourne, E. D.1998. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine. 16: 9, 1009-1015.
[26]  Johansson, B.E. 1999. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine . 17: 10, 2073-2080.
[27]  Johansson, B.E., Wyer, P.C., and Dayan, P.S., 2000. Preliminary Calculation of Institution and Practitioner Specific Rule-in Rates for Bacteremia and Urinary Tract Infection as a First Step in Development of a Decision-tool-based Clinical Policy for the Evaluation of Non-toxic Febrile Infants in an Urban Pediatric Emergency Department. Academic Emergency Medicine 7: 5, 570
[28]  Johansson, B.E., Pokorny, B.A. and Tiso, V.A. 2002. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidase induces a balanced immune response without antigenic competition. Vaccine. 20: 1670-74.
[29]  Kilbourne, E.D., Smith, C., Brett, I.C., Pokorny, B.A., Johansson, B.E., and Cox, N. 2002. The total influenza vaccine failure of 1947 revisited: Major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci, USA. 99: 16, 10748-52.
[30]  Johansson, B. and Brett, I. 2003. Variation in cation requirements of influenza A N2 neuraminidases. J Biochemistry. 134, 345-352.
[31]  Kilbourne, E.D., Johansson, B.E., Pokorny, B.A., Tiso, V. A., Milev, Y., and Matthews, J.T. 2004. Protection of mice with recombinant influenza virus neuraminidase. J Inf. Dis. 189: 456-461.
[32]  Brett, I.C. and Johansson, B. E. 2005. Immunization against Influenza A virus: Comparison of conventional inactivated, live attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology. 339: 2; 273-280.
[33]  Brett, I. C. and Johansson, B.E. 2006. Variation in cation requirements of influenza A N1 neuraminidases. J Biochemistry 139:3, 439-447.
[34]  Johansson, B.E. and Brett, I.C. 2007. "Changing Perspective on Immunization Against Influenza" Supplement: World Congress on Vaccines and Immunology.Vaccine. 25:(16): 3062-5
[35]  Johansson, B. and Brett, I., 2008. Recombinant Influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce better homotypic and broader heterovariant protection in mice. HumanVaccine 4: 6 November/December
[36]  Wohlert, S., Klee, D., Johansson, B., and Hocker, H. (in press) Preparation and immobilization of neuraminidase-inhibitor derivatives to polymer surfaces for binding of influenza A virus neuraminidase. J. Virol Methods.
[37]  Johansson, B.E. 1999. "Influenza Vaccines: A model for immunization with combinations of antigens" In: Combination Vaccines. R. Ellis (Ed). Plenum Press, New York.
[38]  Johansson, B.E. 2006. "Upper Respiratory Disease" Society for Critical Care Medicine, PICU Coursebook: www.sccm.org/SCCM/Specialties/Pediatrics/PICU+Course/
[39]  Johansson, B.E. 2006."Lower Respiratory Disease" Society for Critical Care Medicine, PICU Coursebook: www.sccm.org/SCCM/Specialties/Pediatrics/PICU+Course/
[40]  Johansson, B. E. and Hoffman, T. T. 2007. "Pediatric Cardiology: A Practical Review" Published online: http://groups.google.com/group/cctp?hl=en.pedscardiology/file
[41]  McMurry, J. A. , Johansson, B.E., De Groot, A.S. 2008 "T cell directed influenza vaccines" Human Vaccine Vol 4, Issue 1
[42]  Brett, I.C. and Johansson, B.E. 2008. "Mouse models for influenza vaccination" In: Handbook on Immunosenescence: Basic understanding and clinical applications (1st Edition) T. Fulop, G. Pawelec Cl, Franceschi, and K. Hirokawa (Editors) Springer, New York.
[43]  McMurry JA, Johansson BE, Moise L, Martin WD, Malone RW, De Groot AS. 2008 "A call to humoral and cellular arms: A case for enlisting cognate T cell help to develop broad-spectrum vaccines against influenza." IXth World Congress on Vaccines, Immunization And Immunotherapy; Milan, Italy
[44]  Johansson, B.E., 2008. World Health Organization Meeting on: The Role of Neuraminidase in Inducing Protective Immunity Against Influenza, in conjunction with Third European Scientific Working Group Conference; Vilamoura, Portugal. Proceedings: http://www.who.int/vaccine_research/diseases/influenza/meeting_140908/en/index.html
[45]  Johansson, B.E., and Meyer, G.K. (2008) "Practical Biology: Influenza: A Review for Clinicians. Part 1" International Pediatrics 23: 4
[46]  Johansson, B.E., and Meyer, G.K. (2009) "Practical Biology: Influenza: A Review for Clinicians. Part 2" International Pediatrics 24
[47]  Johansson, B.E., and Eichelberger, M.C. (2010) "Influenza: A Unique Problem in Vaccination" Future Virology 5:5, 651-664.
[48]  Johansson, B.E., and Cox, M.M (in press) "Influenza Viral Neuraminidase: The Forgotten Antigen" Expert Review of Vaccines